Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹108 Cr
Revenue (TTM)
₹114 Cr
Net Profit (TTM)
₹12 Cr
ROE
12.1 %
ROCE
15.8 %
P/E Ratio
9.3
P/B Ratio
0.6
Industry P/E
26.59
EV/EBITDA
5.9
Div. Yield
0 %
Debt to Equity
0
Book Value
₹88
EPS
₹5.5
Face value
10
Shares outstanding
21,040,600
CFO
₹38.33 Cr
EBITDA
₹61.08 Cr
Net Profit
₹85.24 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alpa Laboratories
| -33.4 | -21.6 | -34.4 | -51.5 | -1.3 | 7.0 | 3.2 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Alpa Laboratories
| -37.5 | 14.0 | 64.0 | -20.7 | 117.8 | 120.4 | -34.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alpa Laboratories
|
51.8 | 108.5 | 114.3 | 11.7 | -2.2 | 6.6 | 9.3 | 0.6 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 3,265.0 | 7,519.5 | 1,837.4 | 326.7 | 24.7 | 44.5 | 23 | 11.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
Incorporated
1988
Chairman
Mahendra Singh Chawla
Managing Director
Paresh Chawla
Headquarters
Indore Dist, Madhya Pradesh
Website
Looking for more details about Alpa Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Alpa Laboratories Ltd is ₹51.75 (NSE) and ₹51.56 (BSE) as of 02-Apr-2026 IST. Alpa Laboratories Ltd has given a return of -1.29% in the last 3 years.
The P/E ratio of Alpa Laboratories Ltd is 9.30 times as on 02-Apr-2026, a 65 discount to its peers’ median range of 26.59 times.
The P/B ratio of Alpa Laboratories Ltd is 0.59 times as on 02-Apr-2026, a 87 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
11.23
|
1.28
|
|
2024
|
10.46
|
1.16
|
|
2023
|
8.99
|
0.84
|
|
2022
|
10.38
|
1.20
|
|
2021
|
10.50
|
0.71
|
The 52-week high and low of Alpa Laboratories Ltd are Rs 120.50 and Rs 46.10 as of 03-Apr-2026.
Alpa Laboratories Ltd has a market capitalisation of ₹ 108 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Alpa Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹1.54
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.